

DAFTAR PUSTAKA

1. Cornejo-Juárez P, Vilar-Compte D, Pérez-Jiménez C, Namendys-Silva SA, Sandoval-Hernández S, Volkow-Fernández P. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. *Int J Infect Dis [Internet]*. 2015 Feb 1 [cited 2017 Oct 15];31:e31–4. Available from: <http://www.sciencedirect.com/science/article/pii/S1201971214017408#bib0130> DOI: <https://doi.org/10.1016/j.ijid.2014.12.022>
2. Pradhan NP, Bhat SM, Ghadage DP. Nosocomial infections in the medical ICU: A retrospective study highlighting their prevalence, Microbiological profile and impact on icu stay and mortality. *J Assoc Physicians India*. 2014;62(OCT 2014):18–21.
3. Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SAA, Leblebicioglu H, Mehta Y, et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. *Am J Infect Control [Internet]*. 2016 Dec 1 [cited 2017 Oct 15];44(12):1495–504. Available from: <http://www.sciencedirect.com/science/article/pii/S0196655316308057> DOI: <https://doi.org/10.1016/j.ajic.2016.08.007>
4. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence [Internet]*. 2014 [cited 2017 Oct 15];5(1):4–11. Available from: <http://www.tandfonline.com/doi/abs/10.4161/viru.27372> DOI: <https://doi.org/10.4161/viru.27372>
5. Chelazzi C, Pettini E, Villa G, De Gaudio AR. Epidemiology, associated factors and outcomes of ICU-acquired infections caused by Gram-negative bacteria in critically ill patients: an observational, retrospective study. *BMC Anesthesiol [Internet]*. 2015 Sep 21 [cited 2017 Oct 15];15(1):125. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26392077> DOI: [10.1186/s12871-015-0106-9](https://doi.org/10.1186/s12871-015-0106-9)
6. Vazquez L. Antifungal prophylaxis in immunocompromised patients [Internet]. Vol. 8, *Mediterranean Journal of Hematology and Infectious Diseases*. Catholic University in Rome; 2016 [cited 2017 Oct 28]. p. e2016040. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27648203> DOI: [10.4084/MJHID.2016.040](https://doi.org/10.4084/MJHID.2016.040)
7. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucía P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. *Intensive Care Med [Internet]*. 1997 Jan [cited 2017 Oct 15];23(1):23–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9037636>
8. Trejo-Hernández A, Andrade-Domínguez A, Hernández M, Encarnación S. Interspecies competition triggers virulence and mutability in *Candida albicans*–*Pseudomonas aeruginosa* mixed biofilms. *ISME J [Internet]*. 2014 Oct 17 [cited 2017 Oct 15];8(10):1974–88. Available from: <http://www.nature.com/isme/journal/v8/n10>

- re.com/doifinder/10.1038/ismej.2014.53 DOI: <https://doi.org/10.1038/ismej.2014.53>
9. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot J-P, et al. *Candida* spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. *Intensive Care Med* [Internet]. 2012 Aug 15 [cited 2017 Oct 15];38(8):1272–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22699790> DOI: 10.1007/s00134-012-2584-2
 10. Tan X, Zhu S, Yan D, Chen W, Chen R, Zou J, et al. *Candida* spp. Airway colonization: A potential risk factor for *Acinetobacter baumannii* ventilator-associated pneumonia. *Med Mycol* [Internet]. 2016 Aug 1 [cited 2017 Oct 15];54(6):557–66. Available from: <https://academic.oup.com/mmy/article-lookup/doi/10.1093/mmy/myw009> DOI: <https://doi.org/10.1093/mmy/myw009>
 11. Beveridge TJ. Ultrastructure, Chemistry, and Function of the Bacterial Wall. *Int Rev Cytol*. 1981;72(C):229–317.
 12. Beveridge TJ, Graham LL. Surface layers of bacteria. *Microbiol Rev* [Internet]. 1991 [cited 2017 Oct 22];55(4):684–705. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1723487>
 13. Salton MRJ. The Relationship Between the Nature of the Cell Wall and the Gram Stain. *J Gen Microbiol* [Internet]. 1963 [cited 2017 Oct 22];30(2):223–35. Available from: <http://mic.sgmjournals.org/content/30/2/223.abstract>
 14. Beveridge TJ. Structure of gram-negative cell walls and their derived membrane vesicles. *J Bacteriol*. 1999;181(16):4725–33.
 15. Koebnik R, Locher KP, Van Gelder P. Structure and function of bacterial outer membrane proteins: Barrels in a nutshell [Internet]. Vol. 37, *Molecular Microbiology*. Blackwell Science Ltd; 2000 [cited 2017 Oct 22]. p. 239–53. Available from: <http://doi.wiley.com/10.1046/j.1365-2958.2000.01983.x>
 16. Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. *Nat Rev Microbiol* [Internet]. 2015 Sep 16 [cited 2017 Oct 22];13(10):605–19. Available from: <http://www.nature.com/doifinder/10.1038/nrmicro3525> DOI: <https://doi.org/10.1038/nrmicro3525>
 17. Centers for Disease Control and Prevention (U.S.) O of W and CDCN-ALLI. Principles of epidemiology in public health practice: an introduction to applied epidemiology and biostatistics [Internet]. Self study. 2012 [cited 2017 Oct 22]. xii, 1-93, 2-71, 3-65, 4-87, 5-73, 6-78, 22 pages. Available from: <http://www.cdc.gov/ophss/csels/dsepd/SS1978/SS1978.pdf>
 18. Carroll KC, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, et al. Jawetz, Melnick & Adelberg's medical microbiology. McGraw-Hill Education; 2016.
 19. Schmidt H, Hensel M. Pathogenicity islands in bacterial pathogenesis. *Clin Microbiol Rev*. 2004;17(0893–8512 (Print)):14–56.
 20. Soto GE, Hultgren SJ. Bacterial adhesins: Common themes and variations in architecture and assembly [Internet]. Vol. 181, *Journal of Bacteriology*. American Society for Microbiology (ASM); 1999 [cited 2017 Oct 25]. p.

- 1059–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9973330>
21. Sauer FG, Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bacterial pili: Molecular mechanisms of pathogenesis. *Curr Opin Microbiol.* 2000;3(1):65–72.
22. Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues [Internet]. Vol. 17, *Microbes and Infection*. Elsevier Masson; 2015 [cited 2017 Oct 25]. p. 173–83. Available from: <http://www.sciencedirect.com/science/article/pii/S1286457915000179> DOI: <https://doi.org/10.1016/j.micinf.2015.01.004>
23. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. *Lancet Infect Dis.* 2008;8(1):32–43.
24. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis. *Virulence* [Internet]. 2014 [cited 2017 Oct 27];5(1):213–8. Available from: <http://www.tandfonline.com/doi/abs/10.4161/viru.27024> DOI: <https://doi.org/10.4161/viru.27024>
25. Pierce NF, Greenough WB, Carpenter CC. *Vibrio cholerae* enterotoxin and its mode of action. *Bacteriol Rev* [Internet]. 1971 [cited 2017 Oct 27];35(1):1–13. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC378369/>
26. Raetz CRH, Whitfield C. Lipopolysaccharide Endotoxins. *Annu Rev Biochem* [Internet]. 2002 [cited 2017 Oct 27];71(1):635–700. Available from: <http://www.annualreviews.org/doi/10.1146/annurev.biochem.71.110601.135414> DOI: <https://doi.org/10.1146/annurev.biochem.71.110601.135414>
27. Foxman B. Urinary tract infection syndromes. Occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* [Internet]. 2014 [cited 2017 Oct 27];28(1):1–13. Available from: <https://www.sciencedirect.com/science/article/pii/S0891552013000743> DOI: <https://doi.org/10.1016/j.idc.2013.09.003>
28. Dasgupta S, Das S, Hazra A, Chawan N. Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. *Indian J Crit Care Med* [Internet]. 2015 Jan [cited 2017 Oct 27];19(1):14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25624645> DOI: 10.4103/0972-5229.148633
29. Alves C, Casqueiro J, Casqueiro J. Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab* [Internet]. 2012 Mar [cited 2017 Oct 27];16(7):27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22701840> DOI: 10.4103/2230-8210.94253
30. Cohen J, Pinching AJ, Rees AJ, Peters DK. Infection and Immunosuppression: A study of the infective complications of 75 patients with immunologically-mediated disease. *QJM An Int J Med* [Internet]. 1982 Jan 1 [cited 2017 Oct 27];51(1):1–15. Available from: <https://academic.oup.com/qjmed/article-abstract/51/1/1/1575888> DOI: <https://doi.org/10.1093/oxfordjournals.qjmed.a067702>
31. Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial–fungal

- interactions. *Nat Rev Microbiol* [Internet]. 2010 [cited 2017 Oct 28];8(5):340–9. Available from: <http://www.nature.com/doifinder/10.1038/nrmicro2313> DOI: <https://doi.org/10.1038/nrmicro2313>
32. Akagawa G, Abe S, Yamaguchi H. Mortality of candida albicans-infected mice is facilitated by superinfection of escherichia coli or administration of its lipopolysaccharide. *J Infect Dis* [Internet]. 1995 Jun [cited 2017 Oct 28];171(6):1539–44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7769289>
33. Gale D, Sandoval B. Response of mice to the inoculations of both Candida albicans and Escherichia coli. I. The enhancement phenomenon. *J Bacteriol*. 1957;73(5):616–24.
34. Carlson E. Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. *Infect Immun*. 1983;39(1):193–7.
35. Carlson E, Johnson G. Staphylococcus aureus in the establishment of Protection by Candida albicans of Staphylococcus aureus in the Establishment of Dual Infection in Mice. 1985;50(3):655–9.
36. Hogan DA. Pseudomonas-Candida Interactions: An Ecological Role for Virulence Factors. *Science* (80-) [Internet]. 2002 [cited 2017 Oct 28];296(5576):2229–32. Available from: <http://www.sciencemag.org/cgi doi/10.1126/science.1070784> DOI: 10.1126/science.1070784
37. Davis-Hanna A, Piispanen AE, Stateva LI, Hogan DA. Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. *Mol Microbiol* [Internet]. 2008 Dec 7 [cited 2017 Oct 28];67(1):47–62. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18078440> DOI: 10.1111/j.1365-2958.2007.06013.x
38. Georgopapadakou NH, Walsh TJ. Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies. *Antimicrob Agents Chemother*. 1996;40(2):279–91.
39. Denning DW. Echinocandin antifungal drugs. *Lancet*. 2003;362(9390):1142–51.
40. Bohme A, Karthaus M, Hoelzer D. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? *Cancer Chemotherapy*. 1999;45(3):224–32.
41. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. *Clin Infect Dis*. 2001;32(8):1191–200.
42. Simonetti A, Ottaiano E, Diana M V, Onza C, Triassi M. [Epidemiology of hospital-acquired infections in an adult intensive care unit: results of a prospective cohort study]. *Ann Ig* [Internet]. 2013 [cited 2018 Jul 19];25(4):281–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23703302> DOI: 10.7416/ai.2013.1930
43. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans. *Semin Immunol* [Internet]. 2012 Oct 1 [cited 2018 Jul 19];24(5):331–41. Available from: <https://www.sciencedirect.com/science/article/pii/S1044532312000474> DOI: <https://doi.org/10.1016/j.smim.2012.08.001>

- m.2012.04.008
- 44. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl J-P, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med [Internet]. 2012 Mar [cited 2018 Jul 19];40(3):813–22. Available from: <https://insights.ovid.com/crossref?an=0003246-201203000-00015> DOI: 10.1097/CCM.0b013e318236f297
 - 45. Kett DH, Azoulay E, Echeverria PM, Vincent J-L. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*. Crit Care Med [Internet]. 2011 Apr [cited 2018 Jul 19];39(4):665–70. Available from: <https://insights.ovid.com/crossref?an=00003246-201104000-00008> DOI: 10.1097/CCM.0b013e318206c1ca
 - 46. Arvanitis M, Mylonakis E. Characteristics, Clinical Relevance, and the Role of Echinocandins in Fungal-Bacterial Interactions. Clin Infect Dis. 2015;61(July):S630–4.